Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 8 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 11440883

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  2. US 11433029

    Formulation of an antibody and use thereof

    Takeda Pharmaceutical Company Limited · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  3. US 11434304

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  4. US 11426397

    Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

    Takeda Pharmaceutical Company Limited · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  5. US 11427605

    Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

    Takeda Pharmaceutical Company Limited · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  6. US 11414496

    Anti-CD38 binding domains

    Takeda Pharmaceutical Company Limited · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  7. US 11406710

    Constrained conditionally activated binding proteins

    Takeda Pharmaceutical Company Limited · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  8. US 11407748

    Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

    Takeda Pharmaceutical Company Limited · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  9. US 11407984

    Methods for purification of arysulfatase A

    Takeda Pharmaceutical Company Limited · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  10. US 11401346

    Nucleic acids encoding plasma kallikrein binding proteins

    Takeda Pharmaceutical Company Limited · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  11. US 11390634

    Fused heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  12. US 11390687

    Bispecific antibodies against plasma kallikrein and Factor XII

    Takeda Pharmaceutical Company Limited · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  13. US 11389533

    Method of treating inflammatory bowel disease

    Takeda Pharmaceutical Company Limited · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  14. US 11372002

    Assays for determining plasma kallikrein system biomarkers

    Takeda Pharmaceutical Company Limited · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  15. US 11370803

    Heteroaryl plasma kallikrein inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  16. US 11357832

    Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  17. US 11352356

    Inhibitors of plasma kallikrein and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  18. US 11344610

    Prevention and reduction of blood loss

    Takeda Pharmaceutical Company Limited · Granted May 31, 2022 · Expires May 26, 2042

    granted
  19. US 11340237

    Metabolite biomarkers for diseases associated with the contact activation system

    Takeda Pharmaceutical Company Limited · Granted May 24, 2022 · Expires May 19, 2042

    granted
  20. US 11319286

    Heterocyclic compound and application thereof

    Takeda Pharmaceutical Company Limited · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  21. US 11299533

    Purification of factor VIII subspecies

    Takeda Pharmaceutical Company Limited · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  22. US 11299553

    Anti-plasma kallikrein antibodies

    Takeda Pharmaceutical Company Limited · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  23. US 11292766

    Substituted piperidine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  24. US 11286307

    Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

    Takeda Pharmaceutical Company Limited · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted